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Oral Terbinafine for Treatment of Pulmonary 
Pseudallescheria boydii Infection Refractory 
to Itraconazole Therapy
Pseudallescheria boydii, apparently distributed 
worldwide, has been isolated from soil (1), pollut­
ed streams, and sewage sludge (2). It may cause a 
wide range of clinical syndromes in humans, in­
cluding mycetoma, osteomyelitis, brain abscesses, 
and invasive pulmonary and disseminated infec­
tions in both immunocompetent (3) and immuno­
compromised patients (4). Inmost cases treatment 
of pseudallescheriasis includes surgical debride­
ment and excision of necrotic tissue combined 
with systemic administration of antifungal azole 
therapy. Of the imidazoles, miconazole appears to 
be more active in vitro than ketoconazole (5), and 
parenteral administration should be considered in 
patients with compromised host defenses. Overall, 
however, the antifungal azoles have been used 
with variable success (6), and at present the opti­
mal choice and duration of chemotherapy are un­
known.
We have reported previously a case of pulmonary 
pseudallescheriasis in an immunocompetent host 
due to preceding trauma. The patient initially re­
sponded to treatment with itraconazole (7); how­
ever, after nearly two years of treatment with it­
raconazole, the infection relapsed. We report 
here the successful treatment of the relapsed in­
fection with oral terbinafine*
In 1984 the 28-year-old man was admitted to hos­
pital with a perforating chest wound after having 
fallen on a metal bicycle spoke. The course of dis­
ease was complicated by hematothorax, hemopty­
sis, and several bacterial infections with empyema 
for which he underwent four thoracic surgeries. 
Finally, a right-sided pneumonectomy was per­
formed. The patient was discharged in good con­
dition and recovery was uneventful until the 
summer of 1991, when the patient presented with 
expectoration of small mucus plugs that smelled 
like “French cheese”; this occurred approximate­
ly once every six weeks. The patient was afebrile; 
laboratory tests revealed a hemoglobin level of 9.2 
mmol/1 and a leukocyte count of 7.8 X 109/1. 
Bronchoscopy was unrevealing, but computed to­
mography scan of the chest showed swelling 
around the right hilar stump and several collec­
tions of air. Microscopic examination of the expec­
torated mucus plugs showed hyphal elements, 
and cultures grew Pseudallescheria boydii.
Treatment with oral itraconazole (400 mg/day) was 
initiated, and after three months the patient was
symptom free and mycological cultures were 
negative. However, after 20 months of therapy, the 
patient relapsed again and began expectorating 
mucus plugs every two months,
Pseudallescheria boydii was again isolated from 
culture. At that time the itraconazole serum con­
centration was 5421 fjog/l. Magnetic resonance im­
aging showed a small, high-signal lesion sur­
rounding the bronchial stump, but no evidence of 
cavities. Bronchoscopy revealed the presence of a 
small mucus plug and a loose stitch in the bron­
chial stump. Both were removed, but cultures 
were not performed. Itraconazole therapy was 
continued until June 1994, but, since symptoms 
and positive cultures persisted, therapy was 
changed to oral terbinafine (500 mg/day; Sandoz, 
Switzerland) on compassionate treatment basis.
After four months of therapy, bronchoscopy 
showed no evidence of fungal infection, and cul­
tures were negative. Treatment was continued for 
a total of nine months. No adverse events, includ­
ing liver function abnormalities, were apparent 
during therapy. At present, more than one year af­
ter discontinuation of terbinafine therapy, the pa­
tient is free of symptoms.
The MIC for the six isolates of Pseudallescheria 
boydii cultured from the mucus plugs between 
1984 and 1994 was determined in Sabouraud 
broth at 30°C and in RPM I1640 medium at 37°C 
(Dr. N.S. Ryder, Sandoz Forschungsinstitut, 
Vienna). All isolates were found to be resistant in 
vitro to itraconazole (MIC > 100 |xg/ml) and ter­
binafine (MIC > 100 |JLg/ml).
Infections caused by Pseudallescheria boydii are 
often refractory to antifungal chemotherapy, in­
cluding treatment with antifungal azoles. New 
therapeutic approaches are clearly needed for 
the treatment of infections by this organism. Itra­
conazole has been suggested as a good alternative 
to miconazole for treatment (6, 8), but monitor­
ing of serum levels is required since absorption 
from the gastrointestinal tract after oral adminis­
tration may be variable. It causes only minor gas­
trointestinal side effects but should be avoided in 
patients with liver disease because it has been re­
ported to induce elevations of serum aminotrans­
ferases and, in sporadic cases, severe hepatitis.
Relapse of infection during treatment with itra­
conazole occurred in our patient despite ade­
quate serum concentrations. The presence of a 
loose stitch could have contributed to the relapse 
of infection, but symptoms persisted after the
Vol. 15,1996 Letters 27
stitch had been removed and cultures remained 
positive despite continuous therapy with itracon­
azole.
Terbinafine is an allylamine antifungal agent that 
displays a primary fungicidal action against a 
broad range of dermatophytes, moulds, and 
yeasts (9). However, MICs of terbinafine for 
Pseudallescheria boydii are relatively high, rang­
ing from 10 to > 64 juug/ml (10). Indeed, in our pa­
tient neither itraconazole nor terbinafine showed 
significant in vitro activity against the Pseud­
allescheria boydii isolates, but these results did not 
correlate with the successful clinical response to 
treatment with terbinafine.
A poor correlation between susceptibility results 
and in vivo response has been reported for Pseud­
allescheria boydii (11). Furthermore, since residu­
al serum and tissue levels of itraconazole may have 
been present in our patient directly after switch­
ing therapy to terbinafine, simultaneous expo­
sure of Pseudallescheria boydii to both agents may 
have enhanced the killing of the fungus. The in vi­
tro antifungal activity of amphotericin B in com­
bination with antifungal azoles against Pseudall­
escheria boydii has been studied (12), but little is 
known about the activity of terbinafine com­
bined with azoles. Although both the azole and al- 
lyamine antifungal agents are potent inhibitors of 
fungal ergosterol synthesis, their modes of action 
are different and the combination of these agents 
may provide an important therapeutic option.
Although terbinafine is commonly used for the 
treatment of dermatophytic infections of the skin 
and nails, there is some evidence that it may be ef­
fective for the treatment of systemic fungal infec­
tions (13). Marked improvement or cure was not­
ed in two patients with invasive pulmonary asper­
gillosis, one patient with Aspergillus fumigatus 
osteomyelitis and one kidney transplant recipient 
with a wound infection due to Rhizopus spp. (13). 
All four patients had failed to respond to therapy 
with amphotericin B. Furthermore, one patient 
with bronchopneumonia due to Aspergillus fum i­
gatus and Pseudallescheria boydii was treated 
with terbinafine (G.F. Shiraldi et al, International 
Society for Human and Animal Mycology, 
Adelaide, 1994, Abstract no. 139). Cure of clinical 
signs and symptoms was achieved after eight 
months of therapy, but relapse of Pseudallescheria 
boydii infection occurred five months after discon­
tinuation of terbinafine therapy. Complete recov­
ery was achieved after a second treatment course 
of eight months.
The present case suggests that terbinafine may be 
useful in difficult-to-treat infections, but this 
agent should be considered investigational in the 
treatment of systemic fungal infections until the 
therapeutic outcome has been assessed in more 
patients.Terbinafine is well tolerated, even during 
long-term treatment, and side effects are general­
ly mild to moderate, and transient. The most com­
mon are intestinal discomfort, erythema of the 
skin, and mild elevation of liver enzymes. How­
ever, isolated cases of severe skin reactions, includ­
ing Stevens-Johnsons syndrome and toxic epider­
mal necrolysis, and serious hepatic dysfunction, in­
cluding jaundice, cholestasis, and hepatitis, have 
been reported.
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